480 related articles for article (PubMed ID: 21948477)
1. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation.
Fournier P; Bian H; Szeberényi J; Schirrmacher V
Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477
[TBL] [Abstract][Full Text] [Related]
2. Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application.
Apostolidis L; Schirrmacher V; Fournier P
Int J Oncol; 2007 Nov; 31(5):1009-19. PubMed ID: 17912426
[TBL] [Abstract][Full Text] [Related]
3. Newcastle disease virus: a promising agent for tumour immunotherapy.
Zhao L; Liu H
Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810
[TBL] [Abstract][Full Text] [Related]
4. Generation of a recombinant oncolytic Newcastle disease virus and expression of a full IgG antibody from two transgenes.
Pühler F; Willuda J; Puhlmann J; Mumberg D; Römer-Oberdörfer A; Beier R
Gene Ther; 2008 Mar; 15(5):371-83. PubMed ID: 18200068
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance.
Schirrmacher V
Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571
[TBL] [Abstract][Full Text] [Related]
6. In vivo efficacy of systemic tumor targeting of a viral RNA vector with oncolytic properties using a bispecific adapter protein.
Bian H; Wilden H; Fournier P; Peeters B; Schirrmacher V
Int J Oncol; 2006 Dec; 29(6):1359-69. PubMed ID: 17088973
[TBL] [Abstract][Full Text] [Related]
7. Selective oncolytic effect of an attenuated Newcastle disease virus (NDV-HUJ) in lung tumors.
Yaacov B; Eliahoo E; Lazar I; Ben-Shlomo M; Greenbaum I; Panet A; Zakay-Rones Z
Cancer Gene Ther; 2008 Dec; 15(12):795-807. PubMed ID: 18535620
[TBL] [Abstract][Full Text] [Related]
8. Apoptin enhances the oncolytic properties of Newcastle disease virus.
Wu Y; Zhang X; Wang X; Wang L; Hu S; Liu X; Meng S
Intervirology; 2012; 55(4):276-86. PubMed ID: 21865658
[TBL] [Abstract][Full Text] [Related]
9. Rac1 is required for oncolytic NDV replication in human cancer cells and establishes a link between tumorigenesis and sensitivity to oncolytic virus.
Puhlmann J; Puehler F; Mumberg D; Boukamp P; Beier R
Oncogene; 2010 Apr; 29(15):2205-16. PubMed ID: 20101224
[TBL] [Abstract][Full Text] [Related]
10. Newcastle disease virus as an oncolytic agent.
Ravindra PV; Tiwari AK; Sharma B; Chauhan RS
Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097
[TBL] [Abstract][Full Text] [Related]
11. [Progress in using Newcastle disease virus for tumor therapy: a review].
Wu Y; Hao J; Li D
Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105
[TBL] [Abstract][Full Text] [Related]
12. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy.
Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H
J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956
[TBL] [Abstract][Full Text] [Related]
13. Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy.
Janke M; Peeters B; de Leeuw O; Moorman R; Arnold A; Fournier P; Schirrmacher V
Gene Ther; 2007 Dec; 14(23):1639-49. PubMed ID: 17914407
[TBL] [Abstract][Full Text] [Related]
14. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.
Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK
J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus.
Huang Z; Liu M; Huang Y
Discov Med; 2020; 30(159):39-48. PubMed ID: 33357361
[TBL] [Abstract][Full Text] [Related]
16. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors.
Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H
Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiling in PC12 cells infected with an oncolytic Newcastle disease virus strain.
Balogh A; Bátor J; Markó L; Németh M; Pap M; Sétáló G; Müller DN; Csatary LK; Szeberényi J
Virus Res; 2014 Jun; 185():10-22. PubMed ID: 24637408
[TBL] [Abstract][Full Text] [Related]
18. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus.
Vigil A; Park MS; Martinez O; Chua MA; Xiao S; Cros JF; Martínez-Sobrido L; Woo SL; García-Sastre A
Cancer Res; 2007 Sep; 67(17):8285-92. PubMed ID: 17804743
[TBL] [Abstract][Full Text] [Related]
19. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
[TBL] [Abstract][Full Text] [Related]
20. Human tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus.
Schirrmacher V; Haas C; Bonifer R; Ahlert T; Gerhards R; Ertel C
Gene Ther; 1999 Jan; 6(1):63-73. PubMed ID: 10341877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
